GT Biopharma Statistics
Share Statistics
GT Biopharma has 2.54M
shares outstanding. The number of shares has increased by 17.61%
in one year.
| Shares Outstanding | 2.54M |
| Shares Change (YoY) | 17.61% |
| Shares Change (QoQ) | 13.52% |
| Owned by Institutions (%) | 0% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,220 |
| FTD / Avg. Volume | 0.26% |
Short Selling Information
The latest short interest is 50.64K, so 2% of the outstanding
shares have been sold short.
| Short Interest | 50.64K |
| Short % of Shares Out | 2% |
| Short % of Float | 2.03% |
| Short Ratio (days to cover) | 2.98 |
Valuation Ratios
The PE ratio is -0.44 and the forward
PE ratio is -1.42.
GT Biopharma's PEG ratio is
-0.02.
| PE Ratio | -0.44 |
| Forward PE | -1.42 |
| PS Ratio | 0 |
| Forward PS | 0.3 |
| PB Ratio | -3.47 |
| P/FCF Ratio | -0.45 |
| PEG Ratio | -0.02 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for GT Biopharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.72,
with a Debt / Equity ratio of 0.
| Current Ratio | 0.72 |
| Quick Ratio | 0.72 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-13,162,000 |
| Employee Count | 1 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -23.44% in the
last 52 weeks. The beta is 1.31, so GT Biopharma's
price volatility has been higher than the market average.
| Beta | 1.31 |
| 52-Week Price Change | -23.44% |
| 50-Day Moving Average | 2.33 |
| 200-Day Moving Average | 2.45 |
| Relative Strength Index (RSI) | 57.95 |
| Average Volume (20 Days) | 472,129 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -14.36M |
| Net Income | -13.16M |
| EBITDA | -13.16M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -6.94 |
Full Income StatementBalance Sheet
The company has 3.95M in cash and 0 in
debt, giving a net cash position of 3.95M.
| Cash & Cash Equivalents | 3.95M |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -695.23M |
| Total Assets | 4.23M |
| Working Capital | -1.67M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -12.9M
and capital expenditures 0, giving a free cash flow of -12.9M.
| Operating Cash Flow | -12.9M |
| Capital Expenditures | n/a |
| Free Cash Flow | -12.9M |
| FCF Per Share | -6.8 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
